SGLT-2 Therapy Center

In part 3 of this Exclusive Interview, John Buse talks with Diabetes in Control Publisher Steve Freed about the heart complication and amputation risks on the greater population.

Study findings warrant cautious consideration and discussions about risk vs benefit when considering therapy.

Study assessed association of cancer and sodium glucose transporter 2 expression as well as potential benefit of SGLT-2 treatment.

Which antihyperglycemic agent will provide the greater cognitive benefit in patients who are elderly and have diabetes?

Can canagliflozin affect the progression of kidney disease in patients with type 2 diabetes?

In part 1 of this Exclusive Interview, Javed Butler talks with Diabetes in Control Publisher Steve Freed about the use of SGLT to lower risk of heart disease.

In part 4, the conclusion of this Exclusive Interview, Javed Butler talks with Diabetes in Control Publisher Steve Freed about the use of SGLT2 to help prevent heart failure but not as a current treatment method.

Empagliflozin shows improvements in A1C while also having major adverse effects, but there could be a balance.

Researchers seek development of drug therapies and technologies to assist in achieving additional time in glucose target range and less hypoglycemia.

New SGLT1/SGLT2 inhibitor lowers HbA1c and has less hypoglycemia episodes among people who have type 1 diabetes.